NASDAQ:CRDF Cardiff Oncology Q1 2026 Earnings Report $1.68 +0.07 (+4.35%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$1.70 +0.03 (+1.49%) As of 05/6/2026 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cardiff Oncology EPS ResultsActual EPSN/AConsensus EPS -$0.13Beat/MissN/AOne Year Ago EPSN/ACardiff Oncology Revenue ResultsActual RevenueN/AExpected Revenue$0.09 millionBeat/MissN/AYoY Revenue GrowthN/ACardiff Oncology Announcement DetailsQuarterQ1 2026Date5/14/2026TimeBefore Market OpensConference Call DateThursday, May 14, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Cardiff Oncology Earnings HeadlinesCardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 28, 2026 | globenewswire.comCardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent ActivityApril 27, 2026 | markets.businessinsider.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today. | Brownstone Research (Ad)Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent ActivityApril 27, 2026 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), Revolution Medicines (RVMD)April 21, 2026 | theglobeandmail.comCardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026April 21, 2026 | globenewswire.comSee More Cardiff Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email. Email Address About Cardiff OncologyCardiff Oncology (NASDAQ:CRDF) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments. Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development. These candidates target pathways implicated in tumor immune evasion, with the goal of inducing immunogenic cell death and improving response rates. The company’s strategic approach emphasizes combination regimens, pairing its agents with established immunotherapies to potentially increase efficacy in solid tumors. Since its founding in 2015, Cardiff Oncology has pursued strategic collaborations to accelerate its programs, notably entering a research agreement with Merck & Co. to explore combination studies with pembrolizumab. The company conducts its clinical trials across multiple sites in the United States and internationally, serving a global oncology community committed to developing new therapeutic options for patients with cancer.View Cardiff Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boarding Passes Now Being Issued for the Ultimate eVTOL ArbitrageDigitalOcean’s AI Surge: How Far Can This Rally Go?Years in the Making, AMD’s Upside Movement Has Just BegunCapital One’s Big Bet Faces Rising Credit RiskWestern Digital: The Storage Behemoth Skyrocketing on AI DemandOld Money, New Tech: Western Union's Crypto RebootHow Williams Companies Is Cashing in on the AI Power Boom Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026)W.W. Grainger (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
